

Molecular docking study on the $\alpha 3\beta 2$ neuronal nicotinic acetylcholine receptor complexed with α -Conotoxin GIC

Chewook Lee¹, Si-Hyung Lee¹, Do-Hyoung Kim¹ & Kyou-Hoon Han^{1,2,*}

¹Biomedical Translational Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-806, ²Department of Bioinformatics, University of Science and Technology, Daejeon 305-333, Korea

Nicotinic acetylcholine receptors (nAChRs) are a diverse family of homo- or heteropentameric ligand-gated ion channels. Understanding the physiological role of each nAChR subtype and the key residues responsible for normal and pathological states is important. α -Conotoxin neuropeptides are highly selective probes capable of discriminating different subtypes of nAChRs. In this study, we performed homology modeling to generate the neuronal $\alpha 3$, $\beta 2$ and $\beta 4$ subunits using the x-ray structure of the $\alpha 1$ subunit as a template. The structures of the extracellular domains containing ligand binding sites in the $\alpha 3\beta 2$ and $\alpha 3\beta 4$ nAChR subtypes were constructed using MD simulations and ligand docking processes in their free and ligand-bound states using α -conotoxin GIC, which exhibited the highest $\alpha 3\beta 2$ vs. $\alpha 3\beta 4$ discrimination ratio. The results provide a reasonable structural basis for such a discriminatory ability, supporting the idea that the present strategy can be used for future investigations on nAChR-ligand complexes. [BMB reports 2012; 45(5): 275-280]

INTRODUCTION

Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels found in the neuromuscular junction, and the peripheral and central nervous systems of both invertebrates and vertebrates. nAChRs can be activated by the endogenous neurotransmitter acetylcholine or the tobacco plant toxin, nicotine, and play essential roles in regulating synaptic transmission signal (1-3). nAChRs form many different molecular subtypes. For example, some neuronal subtypes are comprised of homopentameric arrangements of identical subunits, $(\alpha 7)_5$ and $(\alpha 9)_5$, whereas others have heteropentameric compositions such as

$(\alpha 1)_2\beta 1\gamma\delta$, $(\alpha 3)_2(\beta 2)_3$, and $(\alpha 4)_2(\beta 2)_3$. Such different receptor subtypes possess discrete anatomical locations and are associated with various physiological functions. Dysfunction or dysregulation of nAChRs has been implicated in a variety of neuropsychiatric disease states including schizophrenia, Parkinson, Alzheimer, depression, and nicotine addiction (1). Several drug discovery programs are aimed at developing neuromodulators that selectively act on specific subtypes of nAChRs (3). However, functional and structural differentiation among different nAChR subtypes is a daunting task due to the similarities in the amino acid sequences of individual nAChR subunits and in the overall topology of all nAChR subtypes.

The venom of *Conus* (marine snail) contains hundreds of neurotoxic peptides that are notable for their small size, potency, and subtype selectivity towards various ion channels (4). One of the most common types of *Conus* peptides is the α -conotoxin family that acts at the nAChR subtypes such as singlet $\alpha 7$ (5); doublet $\alpha 3\beta 2$ (6), $\alpha 3\beta 4$ (7), $\alpha 4\beta 2$ (8), and $\alpha 9\alpha 10$ (9); triplet $\alpha 1\beta 1\delta$ (10), $\alpha 3\alpha 7\beta 4$ (11), and $\alpha 6\beta 2\beta 3$ (12); and quartet $\alpha 1\beta 1\gamma\delta$ (8) and $\alpha 1\beta 1\epsilon\delta$ (13) subunit combinations. Alpha-conotoxins are typically composed of fewer than 20 amino acid residues and are compact molecules, as they contain two disulfide bridges. These neuropeptide have been extremely valuable in revealing the anatomical locations of certain nAChR subtypes. Extensive structural characterization and comparison of several α -conotoxins suggested residues that might be important for their subtype recognition specificities Table 1(14-20). In particular, the structural studies on the $\alpha 4/7$ -conotoxins have shown that these toxins with a same " ω -shaped" backbone topology can display a widely different receptor recognition profiles by relying on subtle differences in their surface properties (14, 15, 19, 21). Above all, the precise delineation of contact sites that are responsible for specific recognition between a particular receptor subtype and its ligands requires high-resolution structures of the complexes of many receptor subtypes with various ligands displaying a large window of affinities. Unfortunately, only limited information acquired by x-ray and nuclear magnetic resonance (NMR) methods is available (22-25).

Topologically, nAChRs are composed of five identical or different subunits arranged around the 5-fold pseudo-symmetrical main axis oriented perpendicular to the cell membrane (1). The ligand-binding sites in nAChR are located at the interface be-

*Corresponding author. Tel: +82-42-860-4250; Fax: +82-42-860-4259; E-mail: khhan600@kribb.re.kr
<http://dx.doi.org/10.5483/BMBRep.2012.45.5.275>

Received 17 November 2011, Revised 27 December 2011,
Accepted 11 January 2012

Keyword: α -Conotoxin GIC, Homology modeling, Ligand-docking, Molecular dynamics (MD) simulations, Nicotinic acetylcholine receptors (nAChRs)

tween the extracellular domains (ECDs) of two subunits (e.g., $\alpha 1\gamma$ and $\alpha 1\delta$ subunit interfaces in the case of the muscular nAChR, and $\alpha 3\beta 2$, $\alpha 3\beta 4$, or $\alpha 4\beta 2$ subunit interfaces in the case of the neuronal nAChRs). Since understanding the detailed ligand-receptor contact sites for nAChRs at an atomic resolution is extremely useful, not only for better understanding of the ligand binding mechanism but also for designing potential nAChR-specific neuromodulators, several investigators have tried to experimentally determine the three-dimensional structures of the ECDs from different nAChR subunits. These efforts failed due to the poor solubility of the expressed ECDs (26). However, an x-ray structure of AChBP (PDB ID: 119B), a soluble homolog of nAChR ECD found in in-land snails, became available about a decade ago (22). This publication opened an alternative way for obtaining structural information of ECDs by harnessing *in silico* methods such as homology modeling, molecular dynamics, and ligand docking. Various homology modeled structures of nAChR ECD based on this AChBP structure have been generated and have proven useful in providing reliable knowledge on the high-resolution topology of the pentameric arrangements of nAChR subunits and the potential receptor-bound modes of sev-

eral ligands (2, 25). One drawback of these AChBP-based homology modeled structures has been the limited accuracy of such structures in providing an unambiguous understanding of the ligand binding mechanism of nAChRs and for designing potential neuromodulators, since they are obtained by homology modeling procedures using low sequence homology (only ~25%) between AChBP and nAChR subunits. More recently, the x-ray structure of the ECD from mouse $\alpha 1$ subunit (PDB ID: 2QC1), whose sequence homology with human nAChR subunits is much higher ($\geq 50\%$), became available (24), which has provided a more reliable platform for generation of better homology models of ECDs.

α -Conotoxin GIC (denoted as GIC) is a 16-residue peptide isolated from the venom of the cone snail *Conus geographus* (6). This toxin potently blocks the $\alpha 3\beta 2$ subtype of human nAChR, showing the highest known selectivity (100,000-fold selective for the $\alpha 3\beta 2$ subtype vs. the muscle receptor of nAChR) for neuronal versus muscle subtype of any nicotinic ligand characterized to date. Interestingly, GIC exhibits a high affinity (~1 nM) to the $\alpha 3\beta 2$ receptor subtype, but a much lower (~700-fold) affinity towards the $\alpha 3\beta 4$ subtype, thus is able to differentiate two close-

Table 1. Sequences and nAChR recognition profiles of 5 α -conotoxin subfamilies

Name ^a	Sequence ^b	Specificity
$\alpha 3/5$ sub-family ^c		
GI	ECC NPAC GRHYS C*	$\alpha 1/\gamma$
MI	GRCC HPAC GKNYS C*	$\alpha 1/\gamma$
SI	ICC NPAC GPKYS C*	None
SIA	YCC HPAC GKNFD C*	$\alpha 1/\gamma$
CnIA	GRCC HPAC GKYY S C*	$\alpha 1/\gamma$, $\alpha 1/\delta$
CnIB	CC HPAC GKYY S C*	$\alpha 1/\gamma$, $\alpha 1/\delta$
$\alpha 3/3$ sub-family		
ImI	GCC SDPRC AWR C*	$\alpha 3/\beta 2 > \alpha 7 > \alpha 3/\beta 4$
ImII	ACC SDRRC RWR C*	$\alpha 7 \cong \alpha 1/\delta$, $\alpha 1/\epsilon > \alpha 3/\beta 2$
$\alpha 4/4$ sub-family		
BulA	GCC STPPC AVLY C*	$\alpha 6/\beta 2 > \alpha 6/\beta 4 \cong \alpha 3\beta 2 > \alpha 3/\beta 4$ $\cong \alpha 4/\beta 4 > \alpha 2/\beta 4 \cong \alpha 7$
$\alpha 4/6$ sub-family		
AuIB	GCCSYPPCFATNPD C*	$\alpha 3/\beta 4$
$\alpha 4/7$ sub-family		
EI ^c	RDOCCYHPTCNMSNPQIC*	$\alpha 1/\delta$
MI	GCCSNPVCHLEHSNLC*	$\alpha 6/\beta 2 \cong \alpha 3/\beta 2 > \alpha 4/\beta 2 \cong \alpha 3/\beta 4$
PnIA	GCCSLPPCAANNPDYC*	$\alpha 3/\beta 2 > \alpha 7 > \alpha 3/\beta 4$
PnIB	GCCSLPPCALSNPDYC*	$\alpha 7 > \alpha 3/\beta 2$
AuIA	GCCSYPPCFATNSDYC*	$\alpha 3/\beta 4$
AuIC	GCCSYPPCFATNSGYC*	$\alpha 3/\beta 4$
Epl	GCCSDPRCNMNNPDYC*	$\alpha 3/\beta 2 \cong \alpha 3/\beta 4$
GID ^d	IRDr CCNPNACRVNNOHVC*	$\alpha 3/\beta 2 \cong \alpha 7 > \alpha 4/\beta 2$
GIC	GCCSHPACAGNNOHIC*	$\alpha 3/\beta 2 \cong \alpha 6/\beta 2 > \alpha 4/\beta 2 \cong \alpha 3/\beta 4$
PIA	RDPCCSNPVCTVHNPQIC*	$\alpha 6/\beta 2 > \alpha 6/\beta 4 \cong \alpha 3/\beta 2 > \alpha 3/\beta 4$
OmlA	GCCSHPACNVNPHICG*	$\alpha 4/\beta 2$

^aThe first capital letter indicates the species origin. ^bThe asterisk indicates an amidated C-terminus. ^cFor the $\alpha 3/5$ sub-family and α -conotoxin EI the specificity is for *Torpedo* receptor. ^d γ , γ -carboxyglutamic acid; O, γ -hydroxyproline

ly-related neuronal nAChR subtypes. Little is known at a structural level as to how G1C can exhibit differential binding affinities towards two different neuronal nAChR subtypes. Here, we explored a combined *in silico* method (homology modeling, molecular dynamics simulations, and docking) to understand the structural basis for such a huge receptor subtype discriminatory ability of G1C.

RESULTS AND DISCUSSION

For a few decades, an important issue in the nAChR field has been how to obtain detailed information about ligand-nAChR interactions in the absence of high-resolution three-dimensional structures of ligand-nAChR complexes. Two alternative strategies have been used to study the mechanism of ligand-nAChR interactions. The first is to delineate receptor residues that might interact with ligands through receptor modification by chemical or biochemical means. Several potential ligand-binding residues have been suggested from studies using mutant receptors and affinity labeled receptors (27-30). Ligand binding modes of these residues have been confirmed in recent homology modeled structures of nAChRs (31) and the x-ray structures of AChBP bound to α -conotoxins (23, 25, 32) or α -cobratoxin (33). Another strategy for studying nAChR-ligand interactions has been to identify potential receptor-binding pharmacophores within various ligands including α -conotoxins (16, 17, 19, 21, 34-37). Here, we have generated high-resolution structures of ligand-nAChR complexes using α -conotoxin G1C, a well-known antagonistic ligand of nAChRs, and the extracellular domains of nAChRs that are homology modeled using the $\alpha 1$ subunit of mouse, which has much higher sequence homology with nAChR subunits than acetylcholine binding protein (AChBP).

Homology modeling of individual subunits of human nAChRs

The three-dimensional structures of individual human nAChR subunits ($\alpha 3$, $\beta 2$, and $\beta 4$) were obtained by homology modeling procedure using MODELLER v9.8 (38) taking the x-ray structure of mouse $\alpha 1$ subunit as a template. The amino acid sequence of the human $\alpha 1$ subunit aligned by the LALIGN program (39) revealed a high sequence homology (95.2%) to that of mouse $\alpha 1$ (Table 2). Calculated C α root mean square deviation (RMSD) between the mouse $\alpha 1$ and human $\alpha 1$ homology modeled ECD structures is 0.458 Å, indicating that the human $\alpha 1$ ECD structure is essentially

Table 2. Sequence homology between human and mouse nAChR subunits (unit: %)

	Mouse $\alpha 1$	Human $\alpha 1$	Human $\alpha 3$	Human $\beta 2$	Human $\beta 4$
Mouse $\alpha 1$	100				
Human $\alpha 1$	95.2	100			
Human $\alpha 3$	51.9	50.2	100		
Human $\beta 2$	43.4	42.4	48.8	100	
Human $\beta 4$	41.4	41.6	48.1	70.4	100

the same as that of the mouse $\alpha 1$ subunit. Sequence homology among the human $\alpha 3$, $\beta 2$, and $\beta 4$ subunits to the mouse $\alpha 1$ subunit was 51.9%, 43.4%, and 41.4%, respectively. These values were well above the "twilight zone" (i.e., sequence homology of <30%), suggesting the homology modeled ECD structures of these subunits obtained from the mouse $\alpha 1$ subunit template should be reliable. Indeed, C α RMSDs of the human $\alpha 3$, $\beta 2$, and $\beta 4$ ECD structures compared with the x-ray structure of mouse $\alpha 1$ ECD were 0.682 Å, 0.205 Å, and 0.258 Å, respectively, confirming that the ECD structures of three subunits were reasonably modeled.

Conformational properties of pentameric nAChRs

The initial pentameric molecular topology for the $\alpha 3\beta 2$ and $\alpha 3\beta 4$ pentameric nAChR subtypes was inferred from the crystal structure of the $\alpha 7$ homopentameric of AChBP (PDB ID: 2C9T) in complex with α -conotoxin 1ml (25). To form the heteropentameric structures, two $\alpha 3$ subunits and three β subunits ($\beta 2$ or $\beta 4$) were substituted into the positions of the $\alpha 7$ subunits at the beginning of the MD simulations. Due to differences in the length and the amino acid composition of each subunit, the structures of the $\alpha 3\beta 2$ pentamer and the $\alpha 3\beta 4$ pentamer differed slightly from that of the $\alpha 7$ pentamer. For example, as shown in Fig. 1a-1c, the bottom portions of the ECD in the $\alpha 3\beta 2$ and $\alpha 3\beta 4$ pentamers were slightly wider than that in the $\alpha 7$ pentamer.




Fig. 1. Structures of three pentameric nAChR subtypes (a) ($\alpha 7$)₅ extracted from PDB 2C9T, (b) ($\alpha 3$)₂($\beta 2$)₃, and (c) ($\alpha 3$)₂($\beta 4$)₃ obtained by 10 ns MD simulations (top panel: side-view, middle panel: top-view). The $\alpha 7$ subunits in (a) are presented in red and green. All $\alpha 3$ subunits in (b) and (c) are shown in red and $\beta 2$ and $\beta 4$ subunits in green. C α RMSD (d) and radius of gyration (e) of $\alpha 3\beta 2$ dimer (black), $\alpha 3\beta 2$ -G1C complex (blue), $\alpha 3\beta 4$ dimer (gray), and $\alpha 3\beta 4$ -G1C complex (red) from the initial structures as a function of simulation time at 300K under the TIP3P explicit water condition.




Fig. 2. The space-filling model structures of the dimer interfaces with and without GIC. Panels (a-d) depict $\alpha 3\beta 2$ dimer, $\alpha 3\beta 2$ -GIC complex, $\alpha 3\beta 4$ dimer, and $\alpha 3\beta 4$ -GIC complex, respectively. The $\alpha 3$ subunit is shown in yellow, β subunits ($\beta 2$ and $\beta 4$) are shown in blue, and GIC is shown in pink.

Nevertheless, the pentameric topology of the $\alpha 3\beta 2$ or $\alpha 3\beta 4$ subtypes was well-preserved during the simulation, as evidenced by the $C\alpha$ RMSD and radius of gyration, Rg (Fig. 1d and 1e). In particular, the subunit interfaces were well modeled, so that the C-loop region (or the cholinergic receptor fragment, CRF) in the $\alpha 3$ subunit that contains the major sites for ligand binding was properly positioned for ligand binding.

Ligand docking and MD simulations of the dimeric interfaces

The heteropentameric nAChR subtypes with a composition of $(\alpha m)_2(\beta n)_3$ have two equivalent ligand binding sites at their $\alpha m\text{-}\beta n$ subunit interfaces. Thus, to reduce computational costs, we modeled only the dimeric $\alpha m\text{-}\beta n$ subunit interfaces, rather than performing MD calculations for the entire pentameric structure. The $\alpha 3\beta 2$ and $\alpha 3\beta 4$ dimers were generated by MD simulations at 300K under explicit solvent water molecules. The MD simulation results consisted of two parts: with and without GIC ligand. Each simulation was done for the two subtype interfaces: one for the $\alpha 3\beta 2$ interface and the other for the $\alpha 3\beta 4$. The four resulting structures are shown in Fig. 2. Average RMSD values from initial dimer structures during the last 5 ns were $4.04 (\pm 0.23) \text{ \AA}$ and $4.40 (\pm 0.29) \text{ \AA}$ for the $\alpha 3\beta 2$ dimer and the $\alpha 3\beta 4$ dimer, respectively. The overall dimension of these structures could be estimated from their Rg values (Fig. 1e). The size of the $\alpha 3\beta 2$ dimer was larger than that of the $\alpha 3\beta 4$ dimer (black and grey lines), mostly due to the size differences between the interfaces of α and β subunit. The C-loop cholinergic fragments located in the central region of both dimers were of similar size.

The final structures of MD simulation and ligand docking showing the details of individual residues involved in ligand binding are shown in Fig. 3a and 3b. As described above, all the structures were fairly stable and the structural variations were quite small after 5 ns of MD simulations (Fig. 1d and 1e). The β -strands composing two inner and outer β -sheets in each subunit were well preserved, as was the overall structure of GIC. Rg value of the $\alpha 3\beta 2$ -GIC and $\alpha 3\beta 4$ -GIC complex was $6.62 \pm 0.10 \text{ \AA}$ and $6.49 \pm 0.11 \text{ \AA}$, respectively. The overall binding position in the interface and the orientation of the key hydrophobic side-chains of GIC were fairly well positioned in the hydrophobic pocket of the nAChR subunits. Such a disposition of ligands has been reported for other α -conotoxins (23, 40, 41). GIC displays an affinity that was ~ 700 -fold higher to the $\alpha 3\beta 2$




Fig. 3. Cartoon representations of the docked GIC after 10 ns MD simulations into (a) $\alpha 3\beta 2$ and (b) $\alpha 3\beta 4$ subunit interfaces. The principal subunit $\alpha 3$ is shown in yellow and the complementary subunits ($\beta 2$ and $\beta 4$) are shown in blue. GIC is shown in red. The yellow stick within GIC indicates two disulfide bridges. Note that the C-loop (cholinergic receptor region) of the principal subunit partly wraps up the toxin. (c) Superposition of the key ligand-binding residues in the principal subunit ($\alpha 3$) and the complementary subunits ($\beta 2$ and $\beta 4$). The residues at the $\alpha 3\beta 2$ and at the $\alpha 3\beta 4$ subunit interface are shown in orange and blue, respectively. GIC at the former is represented as a purple rod, whereas that at the latter is shown as a cyan rod. The green arrows point to the main differences between two subtypes interacting with GIC. ($\alpha 3$ subunit: Y92, Y150, Y189, Y196 / $\beta 2$ subunit: W56, V110, F118, L120 / $\beta 4$ subunit: W56, I110, L118, L120).

receptor subtype ($IC_{50} = 1.1 \text{ nM}$) than to the $\alpha 3\beta 4$ subtype ($IC_{50} = 755 \text{ nM}$) (6). Fig. 3c explains how such a difference may manifest on a structural level. For the $\alpha 3\beta 2$ subtype, GIC can have favorable hydrophobic contacts. The side-chains of $\alpha 150Y$, $\alpha 196Y$, $\beta 110V$, and $\beta 118F$ in the $\alpha 3\beta 2$ subtype are more closely located to the ligand than the side-chains of the corresponding residues in the $\alpha 3\beta 4$ subtype. For example, the residual distance during the last 5 ns of simulation between $\alpha 196Y$ and $\beta 118F$ in the $\alpha 3\beta 2$ -GIC subtype ($8.57 \pm 0.53 \text{ \AA}$) was much closer than that of between $\alpha 196Y$ and $\beta 118L$ in $\alpha 3\beta 4$ -GIC subtype ($17.36 \pm 0.49 \text{ \AA}$). Also, the averaged center of mass distance between Tyr196 of α subunit and Cys8 of GIC in the $\alpha 3\beta 2$ -GIC and $\alpha 3\beta 4$ -GIC complex was 10.29 ± 0.55 and $11.05 \pm 0.64 \text{ \AA}$, respectively. In addition the number of hydrophobic residual contacts between the $\alpha 3\beta 2$ subtype and GIC were larger (19.8 ± 2.5) than those found between the $\alpha 3\beta 4$ subtype and GIC (14.6 ± 2.4) during the last 5 ns of MD simulation. Cys191 and Cys192 in the C-loop of α -subunit in the $\alpha 3\beta 2$ subtype strongly interacted with Cys8, Ile15, and Cys16 of GIC (averaged population 64%, $< 9.0 \text{ \AA}$ of center of mass distance) and those in the $\alpha 3\beta 4$ subunit interacted with Cys2, Cys8, and Ala9 of GIC (60%) during last 5 ns of MD simulation. Therefore, the C-loop in α -subunit plays an important role of hydrophobic interaction with GIC. Also, Leu120 of the β -subunit in $\alpha 3\beta 2$ interacted with Ala7 and Ala9 of GIC (averaged population 96%) and Leu168 interacted with Cys3 and Ala9 (99% and 64%, respectively). In the case of $\alpha 3\beta 4$, Leu57 and Leu120 of the β -subunit interacted with Ala9 of GIC (99% and 73%, respectively). Besides these strong hydrophobic interactions, many medium and weak interactions were observed. These interactions are very influential to the binding affinity. Therefore, binding affinity differences are related with the residual contact around the ligand GIC.

In this work, we performed homology modeling of human α

and β subunits and MD simulation on the dimers and pentamers of nAChRs with and without GIC. Homology modeled ECD structures of human nAChR subunits highly resembled the experimentally-determined structure of the mouse nAChR $\alpha 1$ subunit and were used as an input for molecular dynamics simulation to build the pentameric ECD domains in the $(\alpha 3)_2(\beta 2)_3$, and $(\alpha 3)_2(\beta 4)_3$ nAChR subtypes. The difference in binding affinity of GIC towards the two subtypes was fairly well explained in terms of the orientation of the side-chains in the $\alpha 3$ and $\beta 2/\beta 4$ subunits. Our results suggest that the *in silico* approach we have used here is a promising tool for studying other nAChR-ligand interactions at an atomic resolution.

MATERIALS AND METHODS

Homology modeling of the ECD structure for individual subunits of human nAChRs

The three dimensional models of nAChRs subunits were performed with a MODELLER v9.8 (38). Human $\alpha 1$ subunit was almost identical with the mouse $\alpha 1$ subunit. Human $\alpha 3$, $\beta 2$, and $\beta 4$ were also modeled. Sequence homology between human and mouse $\alpha 1$ is shown in Table 2. C α RMSD between them was 0.458 Å. C α RMSD of human $\alpha 3$, $\beta 2$, and $\beta 4$ compared with 2QC1 was 0.682 Å, 0.205 Å, and 0.258 Å, respectively. The results indicated that our models were proper. The dimeric and pentameric structures with GIC were generated by following procedures: (a) the modeled monomeric subunit was aligned to the corresponding monomer unit of 2C9T, (b) substituted to it with corresponding position, and (c) α -conotoxin Iml in 2C9T was substituted to GIC with the same procedures.

Supporting Information

Details of the molecular dynamics simulations and the methods of trajectory analysis are available free of charge at <http://www.bmbreport.org>.

Acknowledgements

This work was supported by a grant from KRIBB Research Initiative Program. The MD simulations were performed by using the supercomputing resources of the Korea Institute of Science and Technology Information (KISTI, KSC-2011-C3-05).

REFERENCES

1. Corringer, P. J., Novere, N. L. and Changeux, J. P. (2000) Nicotinic receptors at the amino acid level. *Annu. Rev. Pharmacol. Toxicol.* **40**, 431-458.
2. Arias, H. R. (2000) Localization of agonist and competitive antagonist binding sites on nicotinic acetylcholine receptors. *Neurochem. Int.* **36**, 595-645.
3. Paterson, D. and Nordberg, A. (2000) Neuronal nicotinic receptors in the human brain. *Prog. Neurobiol.* **61**, 75-111.
4. Myers, R. A., Cruz, L. J., Rivier, J. E. and Olivera, B. M. (1993) Conus peptides as chemical probes for receptors and ion channels. *Chem. Rev.* **93**, 1923-1936.
5. Hu, S.-H., Gehrman, J., Alewood, P. F., Craik, D. J. and Martin, J. L. (1997) Crystal structure at 1.1 Å resolution of α -conotoxin Pn1B: Comparison with α -conotoxins Pn1A and Gl. *Biochemistry* **36**, 11323-11330.
6. McIntosh, J. M., Dowell, C., Watkins, M., Garrett, J. E., Yoshikami, D. and Olivera, B. M. (2002) α -Conotoxin G1C from *Conus geographus*, a novel peptide antagonist of nicotinic acetylcholine receptors. *J. Biol. Chem.* **277**, 33610-33615.
7. Martinez, J. S., Olivera, B. M., Gray, W. R., Craig, A. G., Groebe, D. R., Abramson, S. N. and McIntosh, J. M. (1995). α -Conotoxin EI, A new nicotinic acetylcholine receptor antagonist with novel selectivity. *Biochemistry* **34**, 14519-14526.
8. López-Vera, E., Aguilar, M. B., Schiavon, E., Marinzi, C., Ortiz, E., Restano Cassulini, R., Batista, C. V. F., Possani, L. D., Heimer de la Cotera, E. P., Peri, F., Becerril, B. and Wanke, E. (2007) Novel α -conotoxins from *Conus spurius* and the α -conotoxin EI share high-affinity potentiation and low-affinity inhibition of nicotinic acetylcholine receptors. *FEBS J.* **274**, 3972-3985.
9. McIntosh, J. M., Plazas, P. V., Watkins, M., Gomez-Casati, M. E., Olivera, B. M. and Elgoyhen, A. B. (2005) A novel α -conotoxin, Pe1A, cloned from *Conus pergrandis*, discriminates between rat $\alpha 9\alpha 10$ and $\alpha 7$ nicotinic cholinergic receptors. *J. Biol. Chem.* **280**, 30107-30112.
10. López-Vera, E., Jacobsen, R. B., Ellison, M., Olivera, B. M. and Teichert, R. W. (2007) A novel alpha conotoxin (α -PIB) isolated from *C. purpurascens* is selective for skeletal muscle nicotinic acetylcholine receptors. *Toxicon.* **49**, 1193-1199.
11. Sandall, D. W., Satkunanathan, N., Keays, D. A., Polidano, M. A., Liping, X., Pham, V., Down, J. G., Khalil, Z., Livett, B. G. and Gayler, K. R. (2003) A novel α -conotoxin Identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo. *Biochemistry* **42**, 6904-6911.
12. Cartier, G. E., Yoshikami, D., Gray, W. R., Luo, S., Olivera, B. M. and McIntosh, J. M. (1996) A new α -conotoxin which targets 32 nicotinic acetylcholine receptors. *J. Biol. Chem.* **271**, 7522-7528.
13. Gray, W. R., Luque, A., Olivera, B. M., Barrett, J. and Cruz, L. J. (1981) Peptide toxins from *Conus geographus* venom. *J. Biol. Chem.* **256**, 4734-4740.
14. Chi, S.-W., Kim, D.-H., Olivera, B. M., McIntosh, J. M. and Han, K.-H. (2004) Solution conformation of alpha-conotoxin G1C, a novel potent antagonist of $\alpha 3\beta 2$ nicotinic acetylcholine receptors. *Biochem. J.* **380**, 347-352.
15. Chi, S.-W., Lee, S.-H., Kim, D.-H., Kim, J.-S., Olivera, B. M., McIntosh, J. M. and Han, K.-H. (2005) Solution structure of α -conotoxin P1A, a novel antagonist of $\alpha 6$ subunit containing nicotinic acetylcholine receptors. *Biochem. Biophys. Res. Commun.* **338**, 1990-1997.
16. Chi, S.-W., Park, K.-H., Suk, J.-E., Olivera, B. M., McIntosh, J. M. and Han, K.-H. (2003) Solution conformation of α A-conotoxin E1VA, a potent neuromuscular nicotinic acetylcholine receptor antagonist from *Conus ermineus*. *J. Biol. Chem.* **278**, 42208-42213.
17. Han, K.-H., Hwang, K.-J., Kim, S.-M., Kim, S.-K., Gray, W. R., Olivera, B. M., Rivier, J. and Shon, K.-J. (1997) NMR structure determination of a novel conotoxin, [Pro 7,13] α A-conotoxin P1VA. *Biochemistry* **36**, 1669-1677.

18. Hu, S.-H., Loughnan, M., Miller, R., Weeks, C. M., Blessing, R. H., Alewood, P. F., Lewis, R. J. and Martin, J. L. (1998) The 1.1 Å resolution crystal structure of [Tyr15]Epl, a novel α -conotoxin from *Conus episcopatus*, solved by direct methods. *Biochemistry* **37**, 11425-11433.
19. Park, K.-H., Suk, J.-E., Jacobsen, R., Gray, W. R., McIntosh, J. M. and Han, K.-H. (2001) Solution conformation of α -conotoxin EI, a neuromuscular toxin specific for the $\alpha 1/\delta$ subunit interface of torpedo nicotinic acetylcholine receptor. *J. Biol. Chem.* **276**, 49028-49033.
20. Shon, K.-J., Koerber, S. C., Rivier, J. E., Olivera, B. M. and McIntosh, J. M. (1997) Three-dimensional solution structure of α -conotoxin MII, an $\alpha 3\beta 2$ neuronal nicotinic acetylcholine receptor-targeted ligand. *Biochemistry* **36**, 15693-15700.
21. Cho, J.-H., Mok, K. H., Olivera, B. M., McIntosh, J. M., Park, K.-H. and Han, K.-H. (2000) Nuclear magnetic resonance solution conformation of α -conotoxin AulB, an $\alpha 3\beta 4$ subtype-selective neuronal nicotinic acetylcholine receptor antagonist. *J. Biol. Chem.* **275**, 8680-8685.
22. Brejč, K., van Dijk, W. J., Klaassen, R. V., Schuurmans, M., van der Oost, J., Smit, A. B. and Sixma, T. K. (2001) Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. *Nature* **411**, 269-276.
23. Celie, P. H. N., Kasheverov, I. E., Mordvintsev, D. Y., Hogg, R. C., van Nierop, P., van Elk, R., van Rossum-Fikkert, S. E., Zhmak, M. N., Bertrand, D., Tsetlin, V., Sixma, T. K. and Smit, A. B. (2005) Crystal structure of nicotinic acetylcholine receptor homolog AChBP in complex with an α -conotoxin PnIA variant. *Nat. Struct. Mol. Biol.* **12**, 582-588.
24. Dellisanti, C. D., Yao, Y., Stroud, J. C., Wang, Z.-Z. and Chen, L. (2007) Crystal structure of the extracellular domain of nAChR $\alpha 1$ bound to α -bungarotoxin at 1.94 Å resolution. *Nat. Neurosci.* **10**, 953-962.
25. Ulens, C., Hogg, R. C., Celie, P. H., Bertrand, D., Tsetlin, V., Smit, A. B. and Sixma, T. K. (2006) Structural determinants of selective α -conotoxin binding to a nicotinic acetylcholine receptor homolog AChBP. *Proc. Natl. Acad. Sci. U.S.A* **103**, 3615-3620.
26. Grant, M. A., Gentile, L. N., Shi, Q.-L., Pellegrini, M. and Hawrot, E. (1999) Expression and spectroscopic analysis of soluble nicotinic acetylcholine receptor fragments derived from the extracellular domain of the α -subunit. *Biochemistry* **38**, 10730-10742.
27. Bren, N. and Sine, S. M. (2000) Hydrophobic pairwise interactions stabilize α -conotoxin MI in the muscle acetylcholine receptor binding site. *J. Biol. Chem.* **275**, 12692-12700.
28. Chiara, D. C., Xie, Y. and Cohen, J. B. (1999) Structure of the agonist-binding sites of the torpedo nicotinic acetylcholine receptor: Affinity-labeling and mutational analyses identify γ Tyr-111/ δ Arg-113 as antagonist affinity determinants. *Biochemistry* **38**, 6689-6698.
29. Quiram, P. A., McIntosh, J. M. and Sine, S. M. (2000) Pairwise interactions between neuronal $\alpha 7$ acetylcholine receptors and α -conotoxin PnIB. *J. Biol. Chem.* **275**, 4889-4896.
30. Sugiyama, N., Marchot, P., Kawanishi, C., Osaka, H., Molles, B., Sine, S. M. and Taylor, P. (1998) Residues at the subunit interfaces of the nicotinic acetylcholine receptor that contribute to α -conotoxin M1 binding. *Mol. Pharmacol.* **53**, 787-794.
31. Dutertre, S., Nicke, A., Tyndall, J. D. A. and Lewis, R. J. (2004) Determination of α -conotoxin binding modes on neuronal nicotinic acetylcholine receptors. *J. Mol. Recogn.* **17**, 339-347.
32. Hansen, S. B., Sulzenbacher, G., Huxford, T., Marchot, P., Taylor, P. and Bourne, Y. (2005) Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations. *EMBO J.* **24**, 3635-3646.
33. Bourne, Y., Talley, T. T., Hansen, S. B., Taylor, P. and Marchot, P. (2005) Crystal structure of a CbtX-AChBP complex reveals essential interactions between snake α -neurotoxins and nicotinic receptors. *EMBO J.* **24**, 1512-1522.
34. Fraenkel, Y., Shalev, D. E., Gershoni, J. M. and Navon, G. (1996) Nuclear magnetic resonance (NMR) analysis of ligand receptor interactions: the cholinergic system—a model. *CRC, Crit. Rev. Biochem. Mol. Biol.* **31**, 273-301.
35. Luo, S., Nguyen, T. A., Cartier, G. E., Olivera, B. M., Yoshikami, D. and McIntosh, J. M. (1999) Single-residue alteration in α -conotoxin PnIA switches its nAChR subtype selectivity. *Biochemistry* **38**, 14542-14548.
36. McIntosh, J. M., Azam, L., Staheli, S., Dowell, C., Lindstrom, J. M., Kuryatov, A., Garrett, J. E., Marks, M. J. and Whiteaker, P. (2004) Analogs of α -conotoxin MII are selective for $\alpha 6$ -containing nicotinic acetylcholine receptors. *Mol. Pharmacol.* **65**, 944-952.
37. Mok, K. H. and Han, K.-H. (1999) NMR solution conformation of an antitoxic analogue of α -conotoxin GI: identification of a common nicotinic acetylcholine receptor $\alpha 1$ -subunit binding surface for small ligands and α -conotoxins. *Biochemistry* **38**, 11895-11904.
38. Martí-Renom, M. A., Stuart, A. C., Fiser, A., Sánchez, R., Melo, F. and Šali, A. (2000) Comparative protein structure modeling of genes and genomes. *Annu. Rev. Biophys. Biomol. Struct.* **29**, 291-325.
39. Homer, N., Merriman, B. and Nelson, S. (2009) Local alignment of two-base encoded DNA sequence. *BMC Bioinformatics* **10**, 175.
40. Dutertre, S., Ulens, C., Buttner, R., Fish, A., van Elk, R., Kendel, Y., Hopping, G., Alewood, P. F., Schroeder, C., Nicke, A., Smit, A. B., Sixma, T. K. and Lewis, R. J. (2007) AChBP-targeted α -conotoxin correlates distinct binding orientations with nAChR subtype selectivity. *EMBO J.* **26**, 3858-3867.
41. Le Novère, N., Grutter, T. and Changeux, J.-P. (2002) Models of the extracellular domain of the nicotinic receptors and of agonist- and Ca^{2+} -binding sites. *Proc. Natl. Acad. Sci. U.S.A* **99**, 3210-3215.